Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...
Fierce Biotech13d
Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
Hosted on MSN12d
Curevo procures $110m and former-GSK exec for shingles vaccine candidate
Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
STAT13d
Small vaccine maker names Operation Warp Speed leader as chairman, raises $110 million
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
Endpoints News13d
Cure­vo gets $110M for a shot against Shin­grix, gets Mon­cef Slaoui and Tal Zaks on board
Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's ...
Jose Cuervo Says The Additive-Free Movement Is ‘Damaging’ To Tequila
Jose Cuervo, the world’s top-selling tequila brand, says it is not a supporter of the additive-free campaign that has swept ...
Business Insider14d
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic ...
Morningstar14d
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...